当前位置: X-MOL 学术EBioMedicine › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A peptide derived from the core β-sheet region of TIRAP decoys TLR4 and reduces inflammatory and autoimmune symptoms in murine models.
EBioMedicine ( IF 11.1 ) Pub Date : 2020-01-31 , DOI: 10.1016/j.ebiom.2020.102645
Asma Achek 1 , Hyuk-Kwon Kwon 2 , Mahesh Chandra Patra 1 , Masaud Shah 1 , Riwon Hong 3 , Wang Hee Lee 1 , Wook-Young Baek 4 , Yang Seon Choi 1 , Gi-Young Kim 1 , Thuong L H Pham 1 , Chang-Hee Suh 4 , Wook Kim 1 , Dae-Hyun Hahm 3 , Sangdun Choi 1
Affiliation  

BACKGROUND TLRs are some of the actively pursued drug-targets in immune disorders. Owing to a recent surge in the cognizance of TLR structural biology and signalling pathways, numerous therapeutic modulators, ranging from low-molecular-weight organic compounds to polypeptides and nucleic acid agents have been developed. METHODS A penetratin-conjugated small peptide (TIP3), derived from the core β-sheet of TIRAP, was evaluated in vitro by monitoring the TLR-mediated cytokine induction and quantifying the protein expression using western blot. The therapeutic potential of TIP3 was further evaluated in TLR-dependent in vivo disease models. FINDINGS TIP3 blocks the TLR4-mediated cytokine production through both the MyD88- and TRIF-dependent pathways. A similar inhibitory-effect was exhibited for TLR3 but not on other TLRs. A profound therapeutic effect was observed in vivo, where TIP3 successfully alleviated the inflammatory response in mice model of collagen-induced arthritis and ameliorated the disease symptoms in psoriasis and SLE models. INTERPRETATION Our data suggest that TIP3 may be a potential lead candidate for the development of effective therapeutics against TLR-mediated autoimmune disorders. FUNDING This work was supported by the National Research Foundation of Korea (NRF-2019M3A9A8065098, 2019M3D1A1078940 and 2019R1A6A1A11051471). The funders did not have any role in the design of the present study, data collection, data analysis, interpretation, or the writing of the manuscript.

中文翻译:

源自TIRAP核心β-折叠区域的肽可诱骗TLR4并减轻鼠模型的炎症和自身免疫症状。

背景技术TLR是免疫疾病中一些积极追求的药物靶标。由于最近对TLR结构生物学和信号传导途径的认识激增,已经开发了许多治疗调节剂,其范围从低分子量有机化合物到多肽和核酸试剂。方法通过监测TLRAP介导的细胞因子诱导并使用Western blot定量蛋白质表达,对源自TIRAP核心β-折叠的渗透素缀合小肽(TIP3)进行体外评估。在TLR依赖性体内疾病模型中进一步评估了TIP3的治疗潜力。结果TIP3通过MyD88和TRIF依赖性途径阻断TLR4介导的细胞因子的产生。对TLR3表现出相似的抑制作用,但对其他TLR没有表现出抑制作用。在体内观察到了深刻的治疗效果,其中TIP3成功缓解了胶原诱导的关节炎小鼠模型的炎症反应,并改善了牛皮癣和SLE模型的疾病症状。解释我们的数据表明TIP3可能是开发针对TLR介导的自身免疫性疾病的有效疗法的潜在先导候选者。资助这项工作得到了韩国国家研究基金会的资助(NRF-2019M3A9A8065098、2019M3D1A1078940和2019R1A6A1A11051471)。资助者在本研究的设计,数据收集,数据分析,解释或手稿的撰写中没有任何作用。TIP3成功缓解了胶原诱导的关节炎小鼠模型的炎症反应,并改善了牛皮癣和SLE模型的疾病症状。解释我们的数据表明TIP3可能是开发针对TLR介导的自身免疫性疾病的有效疗法的潜在先导候选者。资助这项工作得到了韩国国家研究基金会的资助(NRF-2019M3A9A8065098、2019M3D1A1078940和2019R1A6A1A11051471)。资助者在本研究的设计,数据收集,数据分析,解释或手稿的撰写中没有任何作用。TIP3成功缓解了胶原诱导的关节炎小鼠模型的炎症反应,并改善了牛皮癣和SLE模型的疾病症状。解释我们的数据表明TIP3可能是开发针对TLR介导的自身免疫性疾病的有效疗法的潜在先导候选者。资助这项工作得到了韩国国家研究基金会的资助(NRF-2019M3A9A8065098、2019M3D1A1078940和2019R1A6A1A11051471)。资助者在本研究的设计,数据收集,数据分析,解释或手稿的撰写中没有任何作用。资助这项工作得到了韩国国家研究基金会的资助(NRF-2019M3A9A8065098、2019M3D1A1078940和2019R1A6A1A11051471)。资助者在本研究的设计,数据收集,数据分析,解释或手稿的撰写中没有任何作用。资助这项工作得到了韩国国家研究基金会的资助(NRF-2019M3A9A8065098、2019M3D1A1078940和2019R1A6A1A11051471)。资助者在本研究的设计,数据收集,数据分析,解释或手稿的撰写中没有任何作用。
更新日期:2020-02-03
down
wechat
bug